Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRT-ESO-A2 in advanced solid tumors
NCT04878484Phase 1Withdrawn
- Sponsor
- Athenex
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
01
Overview
Phase 1, open-label trial of TCRT-ESO-A2 in head and neck cancer (HNC), hepatocellular carcinoma (HCC), squamous cell carcinoma of the lung (LSCC) and 2 more, sponsored by Athenex. Primary endpoint: Dose Limiting Toxicity at Day 28. Planned start Aug 2021; status: withdrawn.
02
Drugs
TCRT-ESO-A2
03
Conditions
head and neck cancer (HNC)hepatocellular carcinoma (HCC)squamous cell carcinoma of the lung (LSCC)synovial sarcoma (SS)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04878484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878484.